These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 30482592)

  • 21. Gene Editing in Sorghum Through Agrobacterium.
    Sander JD
    Methods Mol Biol; 2019; 1931():155-168. PubMed ID: 30652289
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent Advances in Therapeutic Genome Editing in China.
    Yang Y; Wang Q; Li Q; Men K; He Z; Deng H; Ji W; Wei Y
    Hum Gene Ther; 2018 Feb; 29(2):136-145. PubMed ID: 29446996
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ji Luo Elucidates the CRISPR Gene Editing Technology, and How It May Affect Cancer Therapy in the Future.
    Luo J
    Oncology (Williston Park); 2016 Oct; 30(10):879. PubMed ID: 27753053
    [No Abstract]   [Full Text] [Related]  

  • 24. Application of the genome editing tool CRISPR/Cas9 in non-human primates.
    Luo X; Li M; Su B
    Dongwuxue Yanjiu; 2016 Jul; 37(4):214-9. PubMed ID: 27469252
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CRISPR/Cas9-Based Genome Editing in Plants.
    Zhang Y; Ma X; Xie X; Liu YG
    Prog Mol Biol Transl Sci; 2017; 149():133-150. PubMed ID: 28712494
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The multiplexed CRISPR targeting platforms.
    Cao J; Xiao Q; Yan Q
    Drug Discov Today Technol; 2018 Aug; 28():53-61. PubMed ID: 30205881
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human germline editing in the era of CRISPR-Cas: risk and uncertainty, inter-generational responsibility, therapeutic legitimacy.
    Schleidgen S; Dederer HG; Sgodda S; Cravcisin S; Lüneburg L; Cantz T; Heinemann T
    BMC Med Ethics; 2020 Sep; 21(1):87. PubMed ID: 32912206
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Spermatogonial stem cell autotransplantation and germline genomic editing: a future cure for spermatogenic failure and prevention of transmission of genomic diseases.
    Mulder CL; Zheng Y; Jan SZ; Struijk RB; Repping S; Hamer G; van Pelt AM
    Hum Reprod Update; 2016 Sep; 22(5):561-73. PubMed ID: 27240817
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Toolkit of CRISPR-Based Genome Editing Systems in Drosophila.
    Xu J; Ren X; Sun J; Wang X; Qiao HH; Xu BW; Liu LP; Ni JQ
    J Genet Genomics; 2015 Apr; 42(4):141-9. PubMed ID: 25953352
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted Base Editing Systems Are Available for Plants.
    Marzec M; Hensel G
    Trends Plant Sci; 2018 Nov; 23(11):955-957. PubMed ID: 30224156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mosaicism in CRISPR/Cas9-mediated genome editing.
    Mehravar M; Shirazi A; Nazari M; Banan M
    Dev Biol; 2019 Jan; 445(2):156-162. PubMed ID: 30359560
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exogenous gene integration mediated by genome editing technologies in zebrafish.
    Morita H; Taimatsu K; Yanagi K; Kawahara A
    Bioengineered; 2017 May; 8(3):287-295. PubMed ID: 28272984
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Using Microinjection to Generate Genetically Modified Caenorhabditis elegans by CRISPR/Cas9 Editing.
    Iyer J; DeVaul N; Hansen T; Nebenfuehr B
    Methods Mol Biol; 2019; 1874():431-457. PubMed ID: 30353529
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CRISPR-Cas9 technology and its application in haematological disorders.
    Zhang H; McCarty N
    Br J Haematol; 2016 Oct; 175(2):208-225. PubMed ID: 27619566
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cas9 immunity creates challenges for CRISPR gene editing therapies.
    Crudele JM; Chamberlain JS
    Nat Commun; 2018 Aug; 9(1):3497. PubMed ID: 30158648
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CRISPR/Cas9 Genome Editing: A Promising Tool for Therapeutic Applications of Induced Pluripotent Stem Cells.
    Zhang Y; Sastre D; Wang F
    Curr Stem Cell Res Ther; 2018; 13(4):243-251. PubMed ID: 29446747
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery.
    Wang HX; Li M; Lee CM; Chakraborty S; Kim HW; Bao G; Leong KW
    Chem Rev; 2017 Aug; 117(15):9874-9906. PubMed ID: 28640612
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Towards a CRISPR view of early human development: applications, limitations and ethical concerns of genome editing in human embryos.
    Plaza Reyes A; Lanner F
    Development; 2017 Jan; 144(1):3-7. PubMed ID: 28049687
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CRISPR-Cas9: from Genome Editing to Cancer Research.
    Chen S; Sun H; Miao K; Deng CX
    Int J Biol Sci; 2016; 12(12):1427-1436. PubMed ID: 27994508
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TALEN- and CRISPR-enhanced DNA homologous recombination for gene editing in zebrafish.
    Zhang Y; Huang H; Zhang B; Lin S
    Methods Cell Biol; 2016; 135():107-20. PubMed ID: 27443922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.